Regenxbio Inc. (RGNX) Trading Up 6.9%
Regenxbio Inc. (NASDAQ:RGNX)’s share price was up 6.9% during mid-day trading on Friday . The company traded as high as $7.97 and last traded at $7.95, with a volume of 194,740 shares. The stock had previously closed at $7.44.
A number of equities analysts recently issued reports on RGNX shares. Zacks Investment Research lowered Regenxbio from a “hold” rating to a “sell” rating in a report on Tuesday, March 22nd. Morgan Stanley raised their price objective on shares of Regenxbio from $34.00 to $36.00 in a research report on Friday, April 8th. Chardan Capital restated a “buy” rating on shares of Regenxbio in a research report on Tuesday, May 10th. Finally, Piper Jaffray Cos. restated a “buy” rating and issued a $33.00 price objective on shares of Regenxbio in a research report on Tuesday, July 5th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $28.35.
The stock’s 50 day moving average price is $9.88 and its 200-day moving average price is $11.75. The company’s market capitalization is $208.07 million.
Regenxbio (NASDAQ:RGNX) last issued its earnings results on Thursday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by $0.01. Analysts anticipate that Regenxbio Inc. will post ($2.37) earnings per share for the current year.
In other news, insider Fmr Llc sold 18,900 shares of the company’s stock in a transaction dated Monday, April 18th. The shares were sold at an average price of $11.75, for a total value of $222,075.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.